Suven gets fresh product patents overseas

Hyderabad-based biopharmaceutical company Suven Life Sciences announced today that it was granted one product patent each from Australia, Europe, Israel, Hong Kong and Norway corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases.

"The grant claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of Alzheimer's, attention deficient hyperactivity disorder(ADHD), Huntington's disease, Parkinson and Schizophrenia," the company said in a statement.

With these new patents, Suven has a total of 21 granted patents from Australia, 15 from Europe, 16 from Hong Kong, 4 from Israel and 5 from Norway, it said.